BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20740285)

  • 1. [HER2 ASCO guidelines. The answer to everything?].
    Burandt E; Sauter G
    Pathologe; 2010 Oct; 31 Suppl 2():285-91. PubMed ID: 20740285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.
    Sauter G; Lee J; Bartlett JM; Slamon DJ; Press MF
    J Clin Oncol; 2009 Mar; 27(8):1323-33. PubMed ID: 19204209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
    Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
    Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
    Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
    Ross JS
    Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
    JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
    O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
    Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
    Lee JA; Shaheen M; Walke T; Daly M
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
    Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
    J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
    Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
    Diaz NM
    Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic heterogeneity in HER2 testing may influence therapy eligibility.
    Bernasconi B; Chiaravalli AM; Finzi G; Milani K; Tibiletti MG
    Breast Cancer Res Treat; 2012 May; 133(1):161-8. PubMed ID: 21901388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.